AKT1 and lymphoma: Moreover, Miransertib (ARQ 092), a selective allosteric AKT inhibitor, has demonstrated acceptable safety and initial signs of efficacy in phase I trials for various solid tumors [36], lymphoma [37] and glioma [38].